CHICAGO Use of GLP-1 diabetes and weight-loss medications will climb through the rest of this decade and continue to change the way US consumers eat and buy food and beverages, according to new research from Circana
The suspected mechanism is glucagon activity: the glucagon receptor is expressed in certain tissues of the peripheral nervous system, and its chronic activation appears to alter neurosensory signaling in some subjects
Muscle loss creates a shapeless, deflated appearance
The hormone has become more well-known as GLP-1 agonist and GLP1-GIP receptor medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), have become prescribed more often
That premature decision resulted in unnecessary patient angst and interruptions of therapy when pharmacies could not access the FDA-approved drugs for those patients
Is retatrutide faster than semaglutide for weight loss